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aBStract
CONTEXT AND OBJECTIVE: The Wnt pathway is involved in tumorigenesis of several tissues. For this 
reason, we proposed to evaluate Wnt gene expression in endometrial cancer type I. 
DESIGN AND SETTING: Cross-sectional study on materials gathered from the tissue bank of the Depart-
ment of Pathology, Universidade Federal de São Paulo. 
METHODS: Endometrial specimens were obtained from surgeries performed between 1995 and 2005 at 
São Paulo Hospital, Universidade Federal de São Paulo. The material was divided into two groups accord-
ing to tissue type: Group A, atrophic endometrium (n = 15); and Group B, endometrial adenocarcinoma 
(n = 45). We compared the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 
(FZD5) and beta-catenin between endometrial cancer type I and atrophic endometrium. 
RESULTS: Regarding Wnt1, FZD1 and Wnt5a expression, no significant association was observed between 
the groups. A significant association was observed between the groups in relation to FZD5 expression 
(P = 0.001). The proportion of FZD5-positive samples was significantly higher in group A (80.0%) than in 
group B (31.1%). Regarding the survival curve for FZD5 in group B, we did not find any significant associa-
tion between atrophic endometrium and endometrial adenocarcinoma. We also did not find any signifi-
cant association regarding beta-catenin expression (P = 1.000). 
CONCLUSION: FZD5 is downregulated in endometrial adenocarcinoma, in comparison with atrophic en-
dometrium. 
reSUMO 
CONTEXTO E OBJETIVO: A via Wnt está envolvida na tumorigênese de diversos tipos de tecidos. Por essa 
razão, propusemo-nos a avaliar a expressão de genes da família Wnt no câncer endometrial tipo I.
TIPO DE ESTUDO E LOCAL: Estudo transversal com coleta de materiais do banco de tecidos do Departa-
mento de Patologia da Universidade Federal de São Paulo. 
MÉTODOS: Amostras endometriais foram obtidas de cirurgias que ocorreram entre 1995 e 2005 no Hos-
pital São Paulo, Universidade Federal de São Paulo. Foram separados dois grupos segundo o tipo de tecido 
obtido: grupo A, com endométrio atrófico (n = 15); e grupo B, com adenocarcinoma endometrial (n = 45). 
Comparamos a expressão imunoistoquímica de Wnt 1, Frizzled-1 (FZD1), Wnt 5a, Frizzled-5 (FZD 5) e beta-
catenina entre câncer endometrial tipo I e endométrio atrófico. 
RESULTADOS: Na expressão do Wnt1, FZD1 e Wnt5a, não observamos associação significante entre os 
grupos. Na expressão do FZD5, encontramos associação significante entre os grupos (P = 0,001). A pro-
porção de positividade do FZD5 foi significantemente maior no grupo A comparado ao grupo B (31,1%). 
Em relação à curva de sobrevida para o FZD5 no grupo B, não tivemos associação significante entre endo-
métrio atrófico e adenocarcinoma do endométrio. Também não observamos associação significante na 
expressão da beta-catenina (P = 1,000).  
CONCLUSÃO: FZD5 é downregulated no adenocarcinoma endometrial quando comparado ao endo-
métrio atrófico.
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INTRODUCTION
The Wnt family has an important role in tumorigenesis and 
embryogenesis.1-5 Wnts are an evolutionarily highly conserved 
family of genes/proteins that act through three signaling path-
ways.6 The canonical pathway involves regulation of beta-
catenin. Briefly, in the absence of Wnt signaling, a multipro-
tein complex that includes adenomatous polyposis coli (APC), 
glycogen synthase kinase-3 (GSK3) and axin ensures degrada-
tion of beta-catenin, thereby limiting the free intracytoplasmic 
pool of beta-catenin. The presence of Wnt signaling through the 
Frizzled (FZD) receptor and the low-density lipoprotein recep-
tor-related protein 5 and 6 (LRP5/6) receptor complex inacti-
vates GSK3 and causes its dissociation from axin, thereby pre-
venting phosphorylation of beta-catenin. The intracytoplasmic 
pool of beta-catenin thus increases, and it translocates to the 
nucleus, where it complexes with members of the T-cell fac-
tor/lymphocyte enhancement factor (LEF/TCF) family of tran-
scription factors to mediate transcriptional induction of target 
genes such as c-myc, cyclin D, vascular endothelial growth fac-
tor (VEGF) and others.1-5 
In noncanonical or planar cell polarity (PCP) signaling, Wnt 
signaling is transduced through FZD, independent of LPR5/6. This 
pathway mediates cytoskeletal changes through activation of the 
small GTPases Rho and Rac. Another noncanonical Wnt signal-
ing pathway is WntCa2+. Wnt signaling via FZD mediates activa-
tion of heterotrimeric G-proteins, which engage Dsh, phospholi-
pase C calcium-calmodulin kinase 2 (CamK2) and protein kinase 
C (PKC). This pathway modulates cell adhesion and motility.7
A fourth Wnt signaling pathway can be envisaged, since 
Chen et al. demonstrated that adenylyl cyclase signaling via pro-
tein kinase A (PKA) and its target transcription factor cAMP-re-
sponsive element-binding protein (CREB) are required for Wnt-
directed myogenic gene expression. They also showed that Wnt 
proteins can also stimulate CREB-mediated transcription.6,8 
In relation to endometrial cancer, most of the studies that 
have linked Wnt signaling to this disease focused on the role 
of beta-catenin. However, other components of Wnt signaling 
have been highlighted in recent published papers.
OBJECTIVE
To investigate the role of the expression of the proteins Friz-
zled-1, Wnt5a, Frizzled-5 and beta-catenin on atrophic endome-
trial tissues and endometrial cancer, using immunohistochemical 
techniques on tissue microarrays obtained from postmenopause 
women.
METHODS
Endometrial specimens were obtained from operations per-
formed between 1995 and 2005 in the Gynecological Oncol-
ogy Sector of the Universidade Federal de Sao Paulo (Unifesp), 
from patients who underwent laparotomy to treat endometrial 
cancer or hysterectomy to treat benign disease. All tissue sam-
ples obtained over that period were included in the study (conve-
nience sample limited by time). None of the patients had received 
any preoperative therapy. We did not have any sample losses 
because this was a cross-sectional study.
The patients were divided into two groups: Group A, atro-
phic endometrium (n = 15); and Group B, endometrial adeno-
carcinoma (n = 45). 
All the patients had menopausal status at the time of diagno-
sis. All the patients in group B had the endometrioid histological 
subtype of endometrial adenocarcinoma, at a variety of tumor 
grades. The cases of atrophic endometrium (group A) were com-
pared with the endometrial cancer cases Group B, using param-
eters that avoided hormonal interference during the tissue analy-
sis, such as exclusion of menopausal women.
The clinical and surgical staging and histological typing were 
performed in accordance with the classification of the Interna-
tional Federation of Gynecology and Obstetrics.9 The study was 
approved by the Institutional Ethics Committee (Unifesp).
RESULTS
Most of the patients in group B were staged as IB and IC (Table 1). 
In all cases, expression of the markers was found practically only 
in the cytoplasm (Figure 1). 
Regarding Wnt1, FZD1 and Wnt5a expression, no significant 
difference was observed between the groups. 
A significant difference was observed between the groups 
in relation to FZD5 expression (P = 0.001). The proportion 
of FZD5-positive women was significantly higher in group A 
(80.0%) than in group B (31.1%). Regarding the survival curve 
for FZD5 in group B, we did not find any significant difference 
between positive and negative women (Figure 2).
No significant difference in beta-catenin expression was 
observed between patient groups, since the expressions for 
groups A and B were 100% and 95.6%, respectively (P = 1.000).
DISCUSSION
Canonical pathway
Endometrioid endometrial adenocarcinoma is essentially con-
nected with type I endometrial cancer, which in turn correlates 
with hyperestrogenism status. Hence, the key to understanding 
the role of Wnt signaling in type I endometrial cancer is to find 
the link between Wnts and estrogen signaling. Many authors have 
suggested that a mutation of beta-catenin/CTNNB1 in the endo-
metrium would lead to nuclear accumulation of beta-catenin and 
then result in uterine endometrioid cancer.1-3
Pijnenborg et al.3 found nuclear accumulation of beta-catenin 
in 38% of their endometrioid endometrial cancer cases, while 
Kariola et al. found 53% and Schlosshauer et al. found 47%.4,5 On 
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the other hand, we found no difference in beta-catenin expres-
sion between cases of atrophic endometrium and endometrial 
cancer, since both groups stained almost equally in the cyto-
plasm. This may be explained by the fact that beta-catenin has a 
low level of association with endometrial cancer, compared with 
loss of PTEN (phosphatase and tensin homologue protein).6 Fur-
thermore, it seems that PTEN mutations do not cause nuclear 
beta-catenin accumulation in endometrial carcinomas.7
It is possible that beta-catenin has a more important role 
in relation to precursor lesions than in uterine cancer itself. 
Hideyuki et al. found nuclear beta-catenin in 70% of their endo-
metrial hyperplasia samples and 56.7% of their endometrial can-
cer samples. However, they also showed that nuclear staining of 
beta-catenin occurred in the mid-proliferative, late proliferative 
and early secretion phases of the normal endometrium during 
the menstrual cycle. Twelve out of 15 cases (80.0%) during these 
periods showed nuclear staining.8 
All these findings are concordant with reports that correlate 
estrogens with the canonical Wnt pathway, thus suggesting that 
estrogens or estrogen receptors are capable of stimulating beta-
catenin accumulation.10,11 
Comparing lean and obese rats, Zhang et al. found that 
estrogen more strongly induced the antiproliferative genes 
retinaldehyde dehydrogenase-2 and secreted frizzled-related 
protein-4 (a negative regulator of Wnt signaling) in lean rats, 
but had little or no effect on obese rats.12 
Noncanonical pathway
Both groups reached total staining for Wnt5a, and the propor-
tion of FZD5-positive women was significantly higher in group 
A (80.0%) than in group B (31.1%).
It is known that noncanonical signaling can inhibit canoni-
cal signaling through a variety of mechanisms.13 We suggest that 
because of the low proportion of FZD5 positivity in the adeno-
carcinoma group, the noncanonical signaling could not function 
properly and that this subsequently led to development of hyper-
plasia and cancer.
Singleton et al. found that Wnt5a and FZD5 were down-
regulated by bisphenol-A (an estrogen receptor agonist) and 
estradiol.14,15 These findings are concordant with the physiopa-
thology of type I endometrial adenocarcinoma. 
Breast cancer is comparable with endometrial cancer in that 
it is also stimulated by estrogens. Jönsson et al. found that loss 
of Wnt5a protein expression was significantly associated with 
higher histological grade, recurrent disease, early relapse and 
death.16  Similar findings have been reported by others.16-18 
Recently, we advocated the idea that the noncanonical Wnt 
pathway has an important role in ovarian cancer and would lead 
to a worse prognosis. Furthermore, we advocated that beta-
catenin would not play an important role in epithelial ovarian 
Clinical staging – n (%) n = 44
IB 13 (29.5%)
IC 16 (36.4%)
IIA 2 (4.5%)
IIB 5 (11.4%)
IIIA 5 (11.4%)
IIIB 1 (2.3%)
IIIC 2 (4.5%)
Table 1. Clinical staging of patients with endometrial cancer
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Figure 1. Expression of the proteins Wnt1, Wnt5a, Frizzled-1 (FDZ1), 
Frizzled-5 (FDZ5) and beta-catenin in groups A and B.
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cancer.19 However, endometrioid ovarian cancer is an exception 
to this. This neoplasia has a molecular pattern similar to that of 
endometrial adenocarcinoma, with regard to the Wnt pathway. 
In fact, in this respect, we suggest that low activity of the nonca-
nonical Wnt pathway would lead to type I endometrial adeno-
carcinoma. This would reflect the complexity of the Wnt path-
way, in which the concepts of tumor suppressors and promoters 
are fickle. Although we did not find any difference between the 
groups regarding Wnt5a, others have found that it was down-
regulated in endometrial carcinomas, in comparison with nor-
mal tissue.20 
Regarding the survival curve for FZD5, there was a ten-
dency towards better prognosis for FZD5-positive women, but 
this association was not significant. This also strengthens the idea 
that the noncanonical Wnt pathway has a protective function in 
relation to endometrial carcinoma. The more we learn about the 
Wnt family and its interactions, the more we obtain new insights 
into old problems.
CONCLUSION
Wnts can produce different effects depending on the context. 
Here, we showed that FZD5 is downregulated in type I endome-
trial adenocarcinoma, compared with atrophic endometrium. 
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